Thus, if a relative increase of IRS-1 signaling is paramount in the pathogenesis of obesity comorbidities, then a pharmacologic means of restoring IRS-2 signaling might prove to be a viable therapeutic option. The gene discussed is IRS1; the disease is obesity due to melanocortin 4 receptor deficiency.